Cargando…
LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS
Circumscribed low-grade gliomas comprise roughly one-third of pediatric CNS tumors. Most of these tumors are caused by activating mutations in the mitogen-activated protein kinase (MAPK) pathway. Drugs targeting the MAPK pathway are effective in other cancers and are being utilized in low-grade glio...
Autores principales: | Hanzlik, Emily, Archambault, Bridget, Dairi, Mays, Schroeder, Kristin, Patel, Mallika, Lipp, Eric S, Boucree, Song, Peters, Katherine, Ashley, David, Landi, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168132/ http://dx.doi.org/10.1093/neuonc/noab090.132 |
Ejemplares similares
-
LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020) -
LGG-12. TRAMETINIB FOR PEDIATRIC LOW GRADE GLIOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Barbour, Mustafa, et al.
Publicado: (2020) -
LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB
por: Nguyen, Tiffany, et al.
Publicado: (2020) -
LGG-30. TRAMETINIB-ASSOCIATED HYPONATREMIA IN A CHILD WITH LOW GRADE GLIOMA IS NOT SEEN FOLLOWING TREATMENT WITH ALTERNATIVE MEK INHIBITOR
por: Lazow, Margot A, et al.
Publicado: (2020) -
LGG-42. Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy
por: Chan, Priya, et al.
Publicado: (2022)